Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data.
Ad26COVS1
/ adverse effects
Adult
Aged
BNT162 Vaccine
/ adverse effects
COVID-19
/ prevention & control
ChAdOx1 nCoV-19
/ adverse effects
Europe
Humans
Leukopenia
/ etiology
Middle Aged
SARS-CoV-2
/ immunology
Thrombocytopenia
/ etiology
Thromboembolism
/ etiology
Thrombosis
/ etiology
Vaccination
/ adverse effects
Young Adult
Hemorrhage
Myocardial infarction
Severe adverse events
Venous thrombosis
Virus-based COVID-19 vaccines
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
17
09
2021
revised:
07
10
2021
accepted:
19
10
2021
pubmed:
29
10
2021
medline:
29
12
2021
entrez:
28
10
2021
Statut:
ppublish
Résumé
The ChAdOx1 nCoV-19 (ChA) (AstraZeneca) and Ad26.COV2.S (AD26) (Janssen) vaccines are virus-based coronavirus disease 2019 (COVID-19) vaccines used worldwide. In spring 2021, venous blood clots and thrombocytopenia were described in some vaccine recipients. We evaluated the frequency of severe adverse events (SAEs) documented in the EudraVigilance European database in young adult (18-64 years old) and older (≥65 years old) vaccine recipients up to 23 June 2021 and related them to coagulation disorders and arterial, cardiac, and nervous system events. Comparison between the frequency of SAEs and SAE-related deaths in ChA and AD26 vs. BNT162b2 COVID-19 (BNT) (Pfizer/BioNTech) vaccine recipients demonstrated: 1) ChA and AD26 recipients than BNT recipients had higher frequencies of not only SAEs caused by venous blood clots and hemorrhage, but also thromboembolic disease and arterial events, including myocardial infarction and stroke; 2) a corresponding higher frequency of SAE-related deaths. The frequency was higher in both young adults and older adults. Comparison between the frequency of SAEs and SAE-related deaths in AD26 vs. ChA recipients demonstrated in AD26 recipients: 1) lower frequency of thrombocytopenia; 2) lower frequency of SAEs in young adult recipients; 3) higher frequency of SAEs in older recipients. Interestingly, most of the venous thrombotic SAEs associated with ChA and AD26 vaccines were not associated with thrombocytopenia, suggesting that TTS (thrombosis with thrombocytopenia syndrome) is not the only type of thrombosis observed following virus-based vaccines. In conclusion, both virus-based COVID-19 vaccines show more SAEs than BNT, but the frequency of the SAE type in the different age groups differs, suggesting that the mechanisms responsible of SAEs overlap only partly.
Identifiants
pubmed: 34710832
pii: S0896-8411(21)00150-5
doi: 10.1016/j.jaut.2021.102742
pmc: PMC8547775
pii:
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
ChAdOx1 nCoV-19
B5S3K2V0G8
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102742Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Front Immunol. 2021 Aug 13;12:728513
pubmed: 34484238
Pharmacol Res. 2021 Aug;170:105699
pubmed: 34087352
Elife. 2022 Jul 04;11:
pubmed: 35781137
Clin Transl Sci. 2020 Nov;13(6):1077-1086
pubmed: 32315487
Nat Med. 2021 Jul;27(7):1290-1297
pubmed: 34108714
Haematologica. 2022 Apr 01;107(4):947-957
pubmed: 35045692
Sci Transl Med. 2020 Nov 18;12(570):
pubmed: 33139519
Immunol Res. 2020 Oct;68(5):310-313
pubmed: 32946016
J Autoimmun. 2021 Aug;122:102685
pubmed: 34174723
Circ Res. 2019 Jan 18;124(2):315-327
pubmed: 30653442
Rev Esc Enferm USP. 2014 Aug;48(4):739-47
pubmed: 25338257
Nature. 2021 Jul;595(7866):283-288
pubmed: 34010947
Lancet. 2018 Jul 21;392(10143):232-243
pubmed: 30047376
Circ Arrhythm Electrophysiol. 2018 Jul;11(7):e006273
pubmed: 29954742
Blood. 2021 Dec 2;138(22):2256-2268
pubmed: 34587242
J Thromb Haemost. 2021 Jul;19(7):1813-1818
pubmed: 33909350
Autoimmun Rev. 2021 Apr;20(4):102792
pubmed: 33610751
Semin Thromb Hemost. 2012 Nov;38(8):905-7
pubmed: 23086541
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nature. 2021 Aug;596(7873):479-481
pubmed: 34429544
Viruses. 2019 Aug 19;11(8):
pubmed: 31430946
Autoimmun Rev. 2020 May;19(5):102524
pubmed: 32220633
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Vaccine. 2011 Jul 18;29(32):5203-9
pubmed: 21619905
PLoS One. 2012;7(7):e40385
pubmed: 22808149
Drug Saf. 2006;29(5):385-96
pubmed: 16689555
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Autoimmunity. 2005 May;38(3):235-45
pubmed: 16126512
Autoimmun Rev. 2014 Oct;13(10):1064-9
pubmed: 25182200
BMJ. 2021 May 5;373:n1114
pubmed: 33952445
Future Virol. 2016 Sep;11(9):649-659
pubmed: 29527232
Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1287-94
pubmed: 21702073
Blood. 2021 Jul 29;138(4):299-303
pubmed: 33988688
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769